基于病例報告文獻的妊娠期使用磺達肝癸鈉安全性分析
打開文本圖片集
中圖分類號R969.3；R973 文獻標志碼A 文章編號 00-0408（2025）09-099-06
DOI0.6039/j.issn.00-0408.2025.09.4
ABSTRACTOBJECTIVEToevaluate thesafetyoffondaparinux inpregnancyandprovidereferenceforitsrational clinical application.METHODSAsearch wasconducted indatabases including CNKI，Wanfang，PubMed，Embase，andElsevier（the searchtimewasfromtheconstructionofthedatabasetoDecember17，2024）tocollctcasereportliteratureonfondapariuxuse duringpregnancy.Patientdemographicinformation，fondaparinuxuseduringpregnancy，concomitantmedications，clinical manifestations，andtreatment detailswereextractedfordescriptivestatisticalanalysis.RESULTSAtotalof17casereports regardingtheuseoffondaparinux during pregnancywerecolected，involving42patientsfrom1lcountriesand47pregnancy records.Amongthese，2Ocasesinvolvedtheuseoffondaparinuxforthepreventionofpregnancy-relatedvenous thromboembolism （VTE），while27cases werefondaparinux treatmentduetorelatedconditions.Atotalof29occurencesoftepatientsweretreated with fondapariuxduetoa（family）historyofVTE.Nineoccurencesofcomplicated pregnancieswerereported，and35patients hadecordsofcomorbiditiesorrelevant medical histories.Theadverseeventsthatocurredduringpregnancywiththeuseof fondaparinux includepostpartum hemorrhage（7cases）andexcesiveanticoagulationcausedbyinappropriate dosage（1case）.
Among the 7 casesof postpartum hemorrhage，3 caseshada blood loss of no less than 1 0 0 0 m L （including 2 cases with uterine atony），3 cases had a drug discontinuation time of ? 1 2 h CONCLUSIONS Based on the existing literature，the safetyoffondaparinuxduringpregnancyisgenerally manageable，with the main adverse event being postpartum hemorrhage.The dosage，interval between discontinuation， comorbidities/medical history，andconcomitantmedicationsof fondaparinux may be the main causesof its adverse events.
KEYWORDSfondaparinux; pregnancy； safety evaluation;anticoagulation；casereport；literatureanalysis
妊娠期女性與非妊娠期女性相比，發(fā)生靜脈血栓栓塞（venousthromboembolism，VTE）的風險約增加了5倍；而在產(chǎn)褥期，該風險進一步增加至20倍以上，且一直持續(xù)到產(chǎn)后12周。（剩余12143字）